Continuous glucose monitoring (CGM) identifies signs of gestational diabetes earlier than oral glucose tolerance tests, a new study has demonstrated.
According to researchers, CGM could potentially play a pivotal role in providing timely identification of distinct glycaemic patterns indicative of early dysglyceamia.
Between June 2020 and December 2021, the team of researchers analysed CGM-derived glycaemic patterns in 768 participants.
Women with gestational diabetes had a higher mean glucose (109 ± 13 vs 100 ± 8 mg/dL; P < .001) and greater glucose SD (23 ± 4 vs 19 ± 3; P < .001) than those without gestational diabetes throughout the gestational period prior to an oral glucose tolerance test, the study has reported.
In addition, it has shown that women with gestational diabetes spent lesser time in glycaemic ranges of 63-140 mg/dL and 63-120 mg/dL throughout gestation than those without gestational diabetes prior to an oral glucose tolerance test.
The authors said: “CGM could be used in addition to or instead of oral glucose tolerance tests to screen individuals at risk for hyperglycaemia during pregnancy, even as early as the first trimester.
“CGM could potentially play a pivotal role in providing timely identification of distinct glycaemic patterns indicative of early dysglycemia.”
For more information and to read the study, click here.